Capricor Therapeutics Stock (NASDAQ: CAPR)

Capricor Therapeutics (NASDAQ:CAPR) Stock, Quote.Headers.trade-ideas

Capricor Therapeutics

Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.

Health insurance

News

Movers

CAPR

The biotechnology company said deramiocel increased cardiac function based on several different measures.

What&#39;s Going On With Capricor Therapeutics Stock Friday?

Health Care

Markets

Analyst Ratings

Trading Ideas

General

PTCT

SRPT

Pfizer (NYSE: PFE) announced that a phase III study on its mini-dystrophin gene therapy fordadistrogene movaparvovec for treating Duchenne muscular dystrophy (&#34;DMD&#34;) failed to meet the primary endpoint as well as key secondary endpoints.

Pfizer Phase III DMD Gene Therapy Study Misses Goal

pharmaceutical drug medicine FDA

Capricor Therapeutics announced successful completion of a Type-B meeting with the U.S. Food and Drug Administration (FDA).

What&#39;s Going On With Capricor Therapeutics Stock Tuesday?

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics Inc

CAPRAL LTD by Capral Ltd.

Capri Holdings Ltd

CAPRICORN ENRGY U/ADR by CAPRICORN ENERGY PLC

Capricorn Energy PLC

CAPRICORN ENERGY PLC by CAPRICORN ENERGY PLC

Capricorn Energy PLC ADR

CAPRICORN METALS LTD by CAPRICORN METALS LTD.

Capricorn Metals Ltd

Analysts' ratings for Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $27.83, a high estimate of $40.00, and a low estimate of $8.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 8.45%. 
<img src="https://www.benzinga.com/files/images/story/2024/1719921657_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Capricor Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Leland Gershell</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$14.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Aydin Huseynov</td>
<td>Ladenburg Thalmann</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Capricor Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Capricor Therapeutics compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Capricor Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Capricor Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CAPR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Capricor Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Capricor Therapeutics Better</h2>
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.
<h3>Financial Milestones: Capricor Therapeutics's Journey</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Capricor Therapeutics's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 64.29%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Capricor Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -199.6%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Capricor Therapeutics's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -47.73%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Capricor Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -18.11%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.11.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Unveiling 6 Analyst Insights On Capricor Therapeutics

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Buy and maintains $40 price target.

Price Target

Reiteration

HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $40 Price Target

<a href="https://www.globenewswire.com/Tracker?data=l9Zo_XQjcZDTC-EfzBnozI24iSNgPzmZ16plyKPPRqucCnjqRQscyPWNP-stcNvpOHaTX8gNy18LXbpjGeTLzex_zN5qOGjy1xyWoyYa3nVZeebqdjXWB71FFCSi_M-IhkmqO03eS-vXLkVv4Ol2Cs1yIvJHB-UEArrZxWyvjpFC_cd8wKFMONZNCbPbNZLU8c06LiJUGS4tHNINlGmVN1qgqx4FlSh_qz9TtIKPAn68YvFLfUrq_sW5ypVIzuU4IWnrhz7BZ7_XN5mveJlxcA==">Capricor Therapeutics</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is set to join the Russell 2000&#xAE;&nbsp;Index and the broad-market Russell 3000&#xAE;&nbsp;Index, effective at the open of U.S. equity markets today, July 1, 2024.

Capricor Therapeutics To Join Russell 2000 And Russell 3000 Indexes

Capricor Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) shares are trading higher on Friday. The company announced the long-term benefits of deramiocel for the treatment of <a href="https://www.benzinga.com/general/biotech/24/06/39547882/capricor-therapeutics-announces-long-term-benefit-of-deramiocel-in-both-skeletal-muscle-and-cardi">duchenne muscular dystrophy (DMD)</a>.
What Happened: The biotechnology company said deramiocel increased cardiac function based on several different measures.
The study found improvements in left ventricular ejection fraction, left ventricular end systolic volume and left ventricular end diastolic volume. Capricor stated that these measures are considered highly applicable when projecting future outcomes.
The trial also demonstrated increased skeletal function, particularly increased performance of upper limb.
The company based these positive findings off the ongoing HOPE-2 open label extension study. Capricor is expected to present these results at the Parent Project Muscular Dystrophy (PPMD) Annual Conference on Saturday.
Related Link: <a href="https://www.benzinga.com/news/24/06/39545594/wall-streets-most-accurate-analysts-give-their-take-on-3-health-care-stocks-with-over-3-dividend-yie">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields</a>
CAPR Price Action: Capricor Therapeutics shares are trading 4.39% higher at $4.84 at the time of writing per data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Shutterstock/ REDPIXEL.PL

What's Going On With Capricor Therapeutics Stock Friday?

-Results in Performance of the Upper Limb (PUL v2.0) Continue to Show Slowing of Disease Progression in Later-Stage DMD Patients- &nbsp;
-Improvements Seen in Multiple Cardiac Endpoints Demonstrating Stabilization of Cardiac Function Over 3 Years of Treatment-
-Pre-BLA Meeting with FDA Scheduled for Q3 2024 to Discuss Options to Expedite BLA Filing-
-Results to be Presented at PPMD Annual Conference on June 29 in Session titled "Approaches to Alter Progression"-
SAN DIEGO, June 28, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=5JUGf910lk9XY8ykIPpR1N6dUaM33HezNIN945T5c3JLyXUgk_-N8eUXmPocFMTNLOfmdGmImkFljFviqfhCspEGow_KH9urm5P9OkN5sBl2dRkMHCrOMiHS9Wbchc_zV3uN2g3s0HAt8ruT0cjZINAZMb3v4OI4d8jBkWj-JrUDJm0VTHBlPMcINF1dKUfT0TKO7etwsURen2-z95nhhz-Qvz5Ti5kzIyGvRtVN8I5jFq4H55cUKmKWA33chZ_LOFLaHJIkx8-rmJAuTuXGkA==">Capricor Therapeutics</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced additional positive 3-year safety and efficacy results from its ongoing HOPE-2 open label extension (OLE) study with its lead asset, deramiocel (CAP-1002), for the treatment of Duchenne muscular dystrophy (DMD).

Biotech

Capricor Therapeutics Announces Long-Term Benefit Of Deramiocel In Both Skeletal Muscle And Cardiac Function In The HOPE-2 OLE Study In Duchenne Muscular Dystrophy

<a href="https://www.globenewswire.com/Tracker?data=Xhv2XFkFB8yc9s10BuRGieseOhB4fv5swRNhnB2703iNpz75fBBDU5b9uecRLoFs13wShlp39n2t1iK0xgCAhF2y_qV8Fzf1OsLG17kg_3kbMllYODCOhcgb5P7y3ITSZQTz1loRTbq_ty34VIcwStD7l9BHKT_vEFO1DiDkD2v-krXdY1S9nRGBn4ZIDFeNBvHiBonTJByd8lkZvR-CyBlj50mQhnmV4NQuhHVF43Tnc-b09f5pB5VTP6JDSWl__UYWlfn-Y993SAhFTzW6QA==">Capricor Therapeutics</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has scheduled a Pre-BLA (Biologics License Application) meeting with the Company in the third quarter of 2024 for deramiocel&nbsp;(CAP-1002), for the treatment of Duchenne Muscular Dystrophy (DMD). Capricor's goal for this meeting will be to finalize its BLA filing plans based on all currently available data as well as to work with the FDA to outline the rolling BLA submission timeline.

Capricor Therapeutics Announces The FDA Has Scheduled Pre-BLA Meeting With The Company For The Treatment Of Duchenne Muscular Dystrophy

Offerings

Capricor Therapeutics Files For Mixed Shelf Offering Of Up To $150M

Pfizer (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pfe#NYSE">PFE</a>) announced that a phase III study on its mini-dystrophin gene therapy fordadistrogene movaparvovec for treating Duchenne muscular dystrophy (&quot;DMD&quot;) failed to meet the primary endpoint as well as key secondary endpoints.
The global phase III study, CIFFREO is investigating fordadistrogene movaparvovec in patients 4-8 years of age with DMD. A progressive and degenerative disorder, DMD leads to weakness and wasting away of the body&#39;s muscles due to disruption of dystrophin production. The disease usually affects boys and is mostly diagnosed in early childhood.&nbsp;
The primary endpoint of the study was an improvement in motor function among the DMD boys treated with fordadistrogene movaparvovec compared to placebo. The primary endpoint was assessed by change in the North Star Ambulatory Assessment (NSAA) one year after treatment. NSAA is a rating scale used to measure motor abilities. The study also failed to show a significant difference between participants treated with fordadistrogene movaparvovec and placebo for the key secondary endpoints. The study&#39;s key secondary endpoints included 10-meter run/walk velocity and time to rise from floor velocity.
As regards the safety profile of the gene therapy, the adverse events were mostly mild to moderate in nature while the treatment-related serious adverse events responded to clinical management. Pfizer plans to share more detailed results from the study at an upcoming medical&nbsp;meeting.
Year to date, Pfizer&#39;s stock has declined 30.7% against an increase of 28.0% for the industry.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/86/68746.jpg?v=1540169149" /> 
Image Source: Zacks Investment Research
Pfizer has, in the past, faced a couple of setbacks related to its clinical program on fordadistrogene movaparvovec.
In 2021, Pfizer paused the CIFFREO study after the FDA placed a clinical hold on the company&#39;s investigational new drug application for the program after a non-ambulatory participant died in the phase I study&nbsp;on the candidate. The FDA lifted the clinical hold&nbsp;in 2022, and the study resumed.
In May 2024, Pfizer reported the death of a young boy who participated in another phase II study called DAYLIGHT evaluating fordadistrogene movaparvovec for treating DMD in boys aged 2-3 years. The boy received the gene therapy a year back in early 2023. Pfizer said it did not have complete information about whether the death was caused due to the drug and said back then that it was working on learning more details. Following the death in the DAYLIGHT study. Pfizer paused dosing in the crossover arm of the CIFFREO study.
At present, Sarepta Therapeutics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/srpt#NASDAQ">SRPT</a>) is the market leader in the treatment of DMD. Sarepta&#39;s commercial portfolio comprises four drugs for DMD, Exondys 51, Vyondys 53 (golodirsen), Amondys 45 (casimersen) and Elevidys (SRP-9001). Sarepta&#39;s Elevidys is the first and only one-shot gene therapy approved on an accelerated basis by the FDA in June 2023 for treating DMD in the United States. Elevidys achieved nearly&nbsp;$134.0 million&nbsp;in net product revenues in the first quarter of 2024. Sarepta has filed an efficacy supplement to the biologics license application (BLA) to expand the labeled indication of Elevidys and also to convert the accelerated approval to a full one. The FDA decision is expected on Jun 21, 2024.&nbsp;
PTC Therapeutics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ptct#NASDAQ">PTCT</a>) also markets two drugs for treating DMD &mdash; Translarna (approved in the European Union) and Emflaza (approved in the United States). PTC Therapeutics&#39; DMD sales were $161 million in the first quarter of 2024
Earlier this week, Capricor Therapeutics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/capr#NASDAQ">CAPR</a>) announced the successful completion of a Type-B meeting&nbsp;with the FDA related to the BLA filing for its lead pipeline candidate, Deramiocel/CAP-1002 for DMD. The FDA agreed to a pre-BLA meeting based on their review&nbsp;of data from the HOPE -3 pivotal study.&nbsp; Capricor Therapeutics will now begin a rolling BLA filing for Deramiocel&nbsp;in the third quarter of 2024. Final data from the HOPE-3 study is expected in the fourth quarter of 2024
Several other companies like Dyne Therapeutics, Solid Biosciences and Wave Life Sciences, among others, are developing therapies for DMD.
<h3>Zacks Rank</h3>
Pfizer has a Zacks Rank #3 (Hold) currently.
<div class="chart_embed">
<h3>Pfizer Inc. Price and Consensus</h3>
<img alt="Pfizer Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/14/1718268967.png" style="height:265px; width:577px" title="" />
Pfizer Inc. price-consensus-chart | Pfizer Inc. Quote
</div>
<a href="https://www.zacks.com/stock/news/2287702/pfizer-pfe-phase-iii-dmd-gene-therapy-study-misses-goal?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2287702">To read this article on Zacks.com click here.</a>

<h3>Gainers</h3>
<ul>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) shares moved upwards by 11.1% to $1.3 during Tuesday's after-market session. The company's market cap stands at $24.4 million. </li>
<li>Unicycive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNCY#NASDAQ">UNCY</a>) stock increased by 6.09% to $0.69. The company's market cap stands at $26.1 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock increased by 5.71% to $1.11. The company's market cap stands at $7.0 million. </li>
<li>Gossamer Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOSS#NASDAQ">GOSS</a>) stock moved upwards by 4.99% to $0.54. The market value of their outstanding shares is at $121.2 million. </li>
<li>Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) stock moved upwards by 4.86% to $5.82. The market value of their outstanding shares is at $185.1 million. </li>
<li>Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) stock moved upwards by 4.72% to $2.88. The market value of their outstanding shares is at $279.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares fell 15.3% to $0.23 during Tuesday's after-market session. The company's market cap stands at $14.6 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock decreased by 14.88% to $0.4. The company's market cap stands at $5.6 million. </li>
<li>ThermoGenesis Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THMO#NASDAQ">THMO</a>) shares decreased by 14.12% to $0.46. The market value of their outstanding shares is at $3.6 million. </li>
<li>Adlai Nortye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANL#NASDAQ">ANL</a>) stock decreased by 11.5% to $3.31. The company's market cap stands at $122.1 million. </li>
<li>Avid Bioservices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDMO#NASDAQ">CDMO</a>) stock declined by 8.89% to $7.28. The company's market cap stands at $462.1 million. </li>
<li>Immuneering (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>) shares decreased by 8.29% to $1.55. The company's market cap stands at $45.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMIX

BSGM

CDMO

CLDI

GOSS

IMRX

PSTX

THMO

UNCY

VERO

12 Health Care Stocks Moving In Tuesday's After-Market Session

Capricor Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) shares are trading higher Tuesday after the company reported completion of next steps regarding CAP-1002, a potential treatment option for <a href="https://www.benzinga.com/general/biotech/24/06/39271210/capricor-therapeutics-completes-type-b-meeting-with-fda-for-cap-1002-program-for-duchenne-muscula">Duchenne Muscular Dystrophy (DMD)</a>.
The Details: The FDA agreed to a pre-Biologics License Application meeting based on data from two clinical studies, HOPE 2 and HOPE 3. The company can begin its BLA filing with a rolling submission, meaning pre-agreed upon parts can be submitted as they are completed. The rolling submission is planned to begin in the 2024 third quarter.
Dr. Linda Marbán, Capricor&#8217;s CEO stated, &#8220;Furthermore, we are looking forward to our presentation of additional 3-year data from our HOPE-2 OLE study at the upcoming&nbsp;PPMD [Parent Project Muscular Dystrophy] conference&nbsp;which we believe will add further evidence of the efficacy and safety of CAP-1002.&#8221;
How To Buy Capricor Therapeutics Stock
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>)'s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
See Also: <a href="https://www.benzinga.com/news/24/06/39269462/why-calavo-growers-shares-are-trading-higher-by-12-here-are-20-stocks-moving-premarket">Why Calavo Growers Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket</a>
CAPR Price Action: At the time of publication, Capricor Therapeutics stock is trading 3.23% higher at $5.58 according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Michal Jarmoluk from Pixabay

What's Going On With Capricor Therapeutics Stock Tuesday?

--FDA Grants Pre-BLA Meeting Request and Rolling BLA Submission after Review of HOPE-2 and HOPE-2 OLE 3-Year Results--

Capricor Therapeutics Completes Type-B Meeting With FDA For CAP-1002 Program For Duchenne Muscular Dystrophy With Aim To Expedite BLA Pathway

Capricor Therapeutics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/capr#NASDAQ">CAPR</a>), a biotechnology firm focused on innovative therapies for rare diseases, has announced favorable three-year results from the ongoing HOPE-2 open-label extension (OLE) study on CAP-1002 for Duchenne muscular dystrophy.
Patients treated with CAP-1002 showed sustained improvements in upper limb function and cardiac performance compared to an external dataset from Cincinnati Children&#39;s Hospital Medical Center, indicating potential long-term benefits.
<h3>Statistical Significance in Disease Attenuation</h3>
The HOPE-2 OLE study revealed a statistically significant reduction in the decline of upper limb function (PUL 2.0) and stabilization of left ventricular ejection fraction among CAP-1002-treated patients over three years. This contrasts sharply with the expected decline observed in untreated DMD patients, suggesting that CAP-1002 can potentially slow disease progression and improve quality of life.
CAP-1002 has demonstrated a well-tolerated safety profile throughout the study. This favorable safety data supports the continued use of CAP-1002 in treating DMD and provides reassurance for patients and healthcare providers about the long-term use of this therapeutic approach.
<h3>Strategic Pathway to FDA Approval</h3>
Capricor highlighted the significance of these findings in a recent Type-B meeting with the FDA, which could expedite the pathway to the approval of a Biologics License Application (BLA) and commercialization. The company anticipates announcing top-line results from the Phase 3 HOPE-3 pivotal trial by the fourth quarter of 2024.
With continued progress and regulatory engagement, CAP-1002 may soon offer a much-needed therapeutic option for patients battling this debilitating disease.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/1a/68461.jpg?v=160943654" /> 
Image Source: Zacks Investment Research
<h3>Growing Market Prospects for DMD Treatment</h3>
DMD is a serious genetic disorder showing progressive weakness and chronic inflammation of the skeletal, heart and respiratory muscles with mortality at a median age of approximately 30 years. Per Capricor, DMD occurs in approximately one in every 3,500 male births and the patient population is estimated to be approximately 15,000-20,000 alone in the United States.
Going by a Mordor Intelligence report, the DMD treatment market size is estimated at $3.42 billion in 2024, and is expected to reach $8.19 billion by 2029, at a CAGR of 19.1%.
The latest development by Capricor accordingly seems to be a strategic fit and well-timed.
<h3>Share Price Performance</h3>
Over the past year, shares of CAPR have risen 12.7% compared with the industry&#39;s 4.9% growth.
<h3>Zacks Rank &amp; Key Picks</h3>
Capricor currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are Hims &amp; Hers Health (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hims#NYSE">HIMS</a>), Medpace (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/medp#NASDAQ">MEDP</a>) and ResMed (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rmd#NYSE">RMD</a>), each sporting a Zacks Rank #1 (Strong Buy) currently.
Hims &amp; Hers Heath stock has surged 131.3% in the past year. Estimates for the company&#39;s earnings have remained constant at 18 cents for 2024 and increased 3.1% to 33 cents for 2025 in the past 30 days.
HIMS&#39; earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 79.2%. In the last reported quarter, it posted an earnings surprise of a staggering 150%.
Estimates for Medpace&#39;s 2024 earnings per share have moved up to $11.29 from $11.23 in the past 30 days. Shares of the company have surged 84% in the past year compared with the industry&#39;s 4.7% growth.
MEDP&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.8%. In the last reported quarter, it delivered an earnings surprise of 30.6%.
Estimates for ResMed&#39;s fiscal 2024 earnings per share have moved to $7.70 from $7.64 in the past 30 days. Shares of the company have declined 1.8% in the past year against the industry&#39;s rise of 4.9%.
RMD&#39;s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 2.8%. In the last reported quarter, it delivered an earnings surprise of 10.9%.
<a href="https://www.zacks.com/stock/news/2285938/capricor-capr-advances-in-dmd-therapy-with-positive-study-data?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2285938">To read this article on Zacks.com click here.</a>

Earnings

Earnings Beats

Hims & Hers Health, Inc. Class A Common Stock

HIMS

MEDP

Capricor Advances in DMD Therapy With Positive Study Data

Capricor Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/capr#NASDAQ">CAPR</a>) is trading higher Tuesday after the company announced three-year results from the ongoing HOPE-2 open-label extension <a href="https://www.benzinga.com/general/biotech/24/06/39160101/capricor-therapeutics-reports-3-year-efficacy-results-from-hope-2-open-label-extension-study-of-c">study with CAP-1002.</a>
HOPE-2, a Phase 2 clinical study, assessed Capricor&#8217;s CAP-1002 therapy in boys and young men with DMD. According to results, patients treated with CAP-1002 continued to show benefits after 3 years of treatment when compared to an external comparator dataset of similar DMD patients.
&#8220;I am extremely encouraged by these positive results from our HOPE-2 OLE study which continue to support the long-term impact of CAP-1002 for the treatment of DMD,&#8221; said Linda Marbán, Ph.D., Capricor&#8217;s CEO.
The study is currently ongoing and will enter its fourth year.
Capricor Therapeutics plans to present these results at the Parent Project Muscular Dystrophy 30th Annual Conference being held June 27-29, 2024.
Related Link: <a href="https://www.benzinga.com/insights/analyst-ratings/24/06/39161716/expert-outlook-transmedics-gr-through-the-eyes-of-7-analysts">Expert Outlook: TransMedics Gr Through The Eyes Of 7 Analysts</a>
CAPR Price Action: At the time of publication, Capricor Therapeutics shares are trading 4.43% higher at $5.89 per data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: 7433388 from Pixabay.

--Results in Performance of the Upper Limb (PUL 2.0) Continue to Show Benefits in Skeletal Muscle Function After 3 Years of CAP-1002 Treatment (p&lt; 0.001)-- &nbsp;
--Stabilization in Left Ventricular Ejection Fraction (LVEF) Suggests Preservation of Cardiac Function--
--Results Recently Shared with FDA at Type-B Meeting Held in May 2024--
SAN DIEGO, June 04, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Fl2LfjRSdlg5njL-VLWVfIEvawcxeCBJz8KOtf4exyvwhzhdnXt3ULgUykcZ03nLrCOiXHfs94uFRCvHJmECV2GR9IjhO_roEBzHpfm5tPWlFtxd7yX8lyny_OhSOW7rT6kTvFkyHMH51H4LjFKCpMkS8qSoECwMihb9WxHx6_homngYy56k_ioJx7VR4DNMDfB5rcvjrOMfRuZbl0D1RfMszp1mPYqBzk-uqKhCyvpglovgAHNrr_nqpcNhZ76nPupxePZWfcA5W65oUw2vRw==">Capricor Therapeutics</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced positive 3-year results from the ongoing HOPE-2 open-label extension (OLE) study with CAP-1002 for the treatment of Duchenne muscular dystrophy (DMD). Patients treated with CAP-1002 continue to show positive benefits after 3 years of treatment in both the PUL 2.0 and LVEF measures when compared to an external comparator dataset of similar DMD patients (dataset provided by Cincinnati Children's Hospital Medical Center (CCHMC)). Further, CAP-1002 treatment during the HOPE-2-OLE study continues to have a consistently well-tolerated safety profile throughout the study. The Company plans to present these results in more detail at the upcoming <a href="https://www.globenewswire.com/Tracker?data=s1494M2-n8zP0NhgHslDBl8LFmmzh9_v-tUxtPIrRn13iSCEGgh7sQkdvBNfsqdklGH_IVhi9gEviohJvkxyGuN4rLRanVJ34BKopE56wm40y__vP4Uo9f07OgLQ4kKRNRASO4vftpX_iyqinWzBJnlMac5UNfstjEwVWe3cyUB7Ef0ceMug9DH_jqyl5-Mp">Parent Project Muscular Dystrophy (PPMD) 30</a><a href="https://www.globenewswire.com/Tracker?data=TKznchtA-vE-HehqU0f3HpzKLxWpZ8FFYsVrlrradwvoYUZd9DulqLAPB6dWr83x_WNKV9dfD0b7qxjxC2k4VH_2SuSdYyxWOctv9piBdF3fzR7Ehg21jkABZLqHd7wm">th</a><a href="https://www.globenewswire.com/Tracker?data=xW1asqdy9UWzmdGlRbBH4eDod8aFoOehWtv1qOPylJ5wGAoFmQYdPO0zKRip65qc5dGjtUtq6HlEE0cflVSMQ3-uxEm6U3naIBnJbECNQe0q85oiu7FCfrDc1KDfQzC_cgwlh5VYHrVRP1XkZ4M_VA=="> Annual Conference</a> being held June 27-29, 2024.

Capricor Therapeutics Reports 3-Year Efficacy Results From HOPE-2 Open Label Extension Study Of CAP-1002 In DMD

Oppenheimer analyst Leland Gershell initiates coverage on Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Outperform rating and announces Price Target of $14.

Initiation

Oppenheimer Initiates Coverage On Capricor Therapeutics with Outperform Rating, Announces Price Target of $14

During the last three months, 5 analysts shared their evaluations of Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>), revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $30.6, a high estimate of $40.00, and a low estimate of $8.00. Observing a 27.5% increase, the current average has risen from the previous average price target of $24.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1715713257_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Capricor Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aydin Huseynov</td>
<td>Ladenburg Thalmann</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$8.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Capricor Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Capricor Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Capricor Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Capricor Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CAPR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Capricor Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Capricor Therapeutics</h2>
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.
<h3>Unraveling the Financial Story of Capricor Therapeutics</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Capricor Therapeutics displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 1159.3%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -6.3%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Capricor Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -7.32% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -1.59%, the company showcases effective utilization of assets.
Debt Management: Capricor Therapeutics's debt-to-equity ratio is below the industry average at 0.1, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Ratings For Capricor Therapeutics

Ladenburg Thalmann analyst Aydin Huseynov maintains Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Buy and raises the price target from $24 to $25.

Ladenburg Thalmann Maintains Buy on Capricor Therapeutics, Raises Price Target to $25

Cantor Fitzgerald analyst Kristen Kluska reiterates Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Overweight and maintains $8 price target.

Cantor Fitzgerald Reiterates Overweight on Capricor Therapeutics, Maintains $8 Price Target

Guidance

Capricor Therapeutics Expects Available Cash & Equivalents To Be Sufficient To Cover Anticipated Expenses And Capital Requirements Into Q1 Of 2025

Novavax, Capricor Therapeutics, Arcutis Biotherapeutics among healthcare movers

Capricor Therapeutics stock rises, Oppenheimer initiates coverage at Outperform

PTC Therapeutics rallies 18% on EU authorization update for Translarna

Capricor Therapeutics files for $150M mixed shelf

Capricor: Rolling BLA Submission Of CAP-1002 To Get DMD Treatment Program Going

Beyond Elevidys: Unveiling The Competitive Landscape Of Duchenne's Muscular Dystrophy

Capricor gains FDA pre-BLA meeting on deramiocel for Duchenne muscular dystrophy

Oppenheimer analyst Leland Gershell maintained a Buy rating on Capricor Therapeutics (CAPR – Research Report) today and set a price target of $14.0...

Capricor Therapeutics (CAPR) Gets a Buy from Oppenheimer

Capricor Therapeutics to join Russell 2000 Index

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Capricor Therapeutics (CAPR – Research Report), retaining the price target o...

Capricor Therapeutics' CAP-1002 Shows Promise in DMD Treatment: Buy Rating Affirmed Following Positive Clinical Trials

ARQT

BBLG

CPRX

CTLT

EWTX

HSCS

LSDI

MSCLF

NEPH

NTBL

NVAX

PEPG

RGNX

RHHBY

SLDB

TRDA

VRTX

Press Releases

Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy

Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13

Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences

Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway

Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy

Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular Dystrophy

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

Capricor Therapeutics

Capricor Therapeutics (CAPR) Forecast

Capricor Therapeutics (NASDAQ:CAPR) Stock, Quote.Headers.trade-ideas